PYC Therapeutics Limited Stock price

Equities

PYC

AU000000PYC7

Biotechnology & Medical Research

Market Closed - Australian S.E. 09:59:08 2024-03-27 pm EDT 5-day change 1st Jan Change
0.082 AUD -1.20% Intraday chart for PYC Therapeutics Limited -2.38% -25.45%
Sales 2024 * 8M 5.22M Sales 2025 * 8M 5.22M Capitalization 347M 227M
Net income 2024 * -31M -20.23M Net income 2025 * -34M -22.19M EV / Sales 2024 * 38.3 x
Net cash position 2024 * 40.79M 26.62M Net cash position 2025 * 75.26M 49.11M EV / Sales 2025 * 34 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-10.7 x
Employees 5
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.14%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on PYC Therapeutics Limited

1 day-1.20%
1 week-2.38%
Current month+3.80%
1 month-1.20%
3 months-25.45%
6 months+36.67%
Current year-25.45%
More quotes
1 week
0.08
Extreme 0.081
0.08
1 month
0.08
Extreme 0.077
0.09
Current year
0.07
Extreme 0.073
0.12
1 year
0.05
Extreme 0.05
0.12
3 years
0.05
Extreme 0.05
0.19
5 years
0.02
Extreme 0.022
0.21
10 years
0.01
Extreme 0.01
0.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 -
Director of Finance/CFO - -
Director of Finance/CFO 62 17-07-23
Members of the board TitleAgeSince
Director/Board Member 76 21-03-16
Director/Board Member 54 21-03-28
Chairman 76 18-04-10
More insiders
Date Price Change Volume
24-03-28 0.082 -1.20% 1,710,042
24-03-27 0.083 +2.47% 700,058
24-03-26 0.081 -1.22% 1,907,312
24-03-25 0.082 -2.38% 1,852,415
24-03-22 0.084 0.00% 436,808

Delayed Quote Australian S.E., March 27, 2024 at 09:59 pm EDT

More quotes
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company, which offers ribonucleic acid (RNA) therapeutics in patients with unmeet genetic diseases. The Company has RNA targeted therapeutics design capabilities to deliver technologies based on cell penetrating peptides (CPPs) and peptide conjugated phosphorodiamidate morpholino oligomer (PPMOs). The Company develops a pipeline of therapies, including two programs, which are focused on inherited eye diseases and preclinical discovery programs, which are focused on neurodegenerative and kidney diseases. The Company's lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate PYC-001, which is focused on treating autosomal dominant optic atrophy (ADOA). Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.082 AUD
Average target price
0.345 AUD
Spread / Average Target
+320.73%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock PYC Therapeutics Limited - Australian S.E.